<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722342</url>
  </required_header>
  <id_info>
    <org_study_id>PMC_TTAC-0001_04</org_study_id>
    <nct_id>NCT03722342</nct_id>
  </id_info>
  <brief_title>TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma</brief_title>
  <official_title>A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmAbcine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmAbcine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to
      establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in
      combination with pembrolizumab in patients with recurrent glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This was mTPI design to start with optimal dose and next dose level is selected accroding to DLT occurrance</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>During the first cycle (every cycle is 21 days) of treatment</time_frame>
    <description>The frequency and percentage of DLT will be presented by dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the screening visit to the end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>The frequency and percentage of AEs will be presented by dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Presence anti-drug antibody (ADA) will be listed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)</time_frame>
    <description>complete response (CR) or partial response (PR) by RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)</time_frame>
    <description>complete response (CR), partial response (PR) or stable disease (SD) by RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Period from the date of the drug administration to the disease progression time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From screening visit to date of patient's death (assessed up to 2 year after end of treatment visit)</time_frame>
    <description>Period from the date of the drug administration to the patient's death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Cmax</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Maximum concentration of drug by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Cmin</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Minimum concentration of drug by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - AUC0-t</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Area under the curve from baseline to each timepoint by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Tmax</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Time of Cmax by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - CL</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Clearance by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Vd</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Volume of distribution by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Ke</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Elimination rate constant by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - T½</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Half-life by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in concentration of serum angiogenic factor or receptor</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>VEGF, placental growth factor [PLGF], soluble vascular endothelial growth factor receptor [sVEGFR]-2, sVEGFR-1, etc.</description>
  </other_outcome>
  <other_outcome>
    <measure>DCE-MRI</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>Blood flow parameter - iAUC, K-trans</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-L1, VEGFR-2 expression level</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 2 years)</time_frame>
    <description>PD-L1, VEGFR-2 expression level in tumour environment such as tumour, tumour vessel and parenchymal tissue</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>TTAC-0001 and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTAC-0001 and pembrolizumab combination therapy will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTAC-0001 and pembrolizumab combination</intervention_name>
    <description>Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)
Treatment groups: 3 dose levels
Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
Cycle: 3 weeks (21 days per cycle)</description>
    <arm_group_label>TTAC-0001 and pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with primary glioblastoma by histopathological examination and confirmed
             recurrent glioblastoma by magnetic resonance imaging (MRI) scans after completing
             standard of care (Stupp protocol) concomitant temozolomide chemotherapy with
             radiotherapy (CCRT)

          2. At least one confirmed measurable lesion by RANO criteria

          3. Karnofsky Performance Status (KPS) ≥80

          4. A person who satisfies the following criteria in haematologic, renal, and hepatic
             function tests performed within 7 days prior to screening:

               1. Haematologic tests

                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

                    -  Platelets ≥ 100 x 109/L

                    -  Haemoglobin ≥ 9.0 g/dL

               2. Blood coagulation tests

                    -  Prothrombin time (PT) ≤ 1.5 x Upper limit of normal (ULN)

                    -  Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN

               3. Hepatic function tests

                    -  Total bilirubin ≤ 1.5 x UNL

                    -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x
                       ULN (≤ 5 x ULN in case of liver metastasis)

               4. Renal function test

                    -  ≤1.5 × ULN or creatinine clearance (CrCl) ≥30 mL/min for patient with
                       creatinine levels &gt;1.5 × institutional ULN

          5. At least 12 weeks of expected survival time

          6. The patient (or legally acceptable representative if applicable) is able and willing
             to provide written informed consent for the trial

        Exclusion Criteria:

          1. Has a known additional malignancy that is progressing or has required active treatment
             within the past 2 years. (Note: Patients with basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin or carcinoma in situ [e.g., breast carcinoma,
             cervical cancer in situ] controlled by curative therapy are not excluded)

          2. Has received prior radiotherapy within 2 weeks of start of study treatment. Patients
             must have recovered from all radiation-related toxicities, not require
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
             for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease

          3. Has a history of (non-infectious) pneumonitis/interstitial lung diseases that required
             steroids or current pneumonitis/interstitial lung disease

          4. Has an active infection requiring systemic therapy

          5. Uncontrolled hypertension (systolic blood pressure [SBP]&gt; 150 or diastolic blood
             pressure [DBP]&gt; 90 mmHg)

          6. Uncontrolled seizures

          7. Class III or IV heart failure by New York Heart Association (NYHA) classification

          8. Has oxygen-dependent chronic disease

          9. Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar
             disorder etc.). Treated depression with ongoing antidepressant medication is not an
             exclusion

         10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             start of study drug

         11. History of serious gastrointestinal haemorrhage within 6 months prior to start of
             study drug

         12. History of severe arterial thromboembolic event within 12 months of start of study
             drug

         13. Serious grade 4 venous thromboembolic event including pulmonary embolism

         14. History of hypertensive crisis or hypertensive encephalopathy

         15. History of posterior reversible encephalopathy syndrome

         16. Planned surgery within 4 weeks post last dose

         17. Moderate to severe proteinuria as demonstrated by urine dipstick for proteinuria ≥2+.
             For patients with ≥2+ proteinuria on dipstick urinalysis, a urine protein: creatinine
             (UPC) ratio will be determined, or a 24-hour urine collection will be done. Patients
             with a UPC ratio &lt;1 or a 24-hour urine protein &lt;1 gram are eligible

         18. Requiring therapeutic anticoagulation with warfarin at baseline; patients must be off
             warfarin or warfarin-derivative anticoagulants for at least 7 days prior to starting
             study drug; however, therapeutic or prophylactic therapy with low-molecular weight
             heparin is allowed

         19. Not recovered below National Cancer Institute-Common Terminology for Adverse Events
             (NCI-CTCAE) grade 1 or baseline from AEs due to previous therapy (patient with ≤ Grade
             2 neuropathy or alopecia may be eligible)

         20. Treatment with systemic chemotherapy, hormonal therapy, immunotherapy or biologic
             therapy within 2 weeks prior to the baseline visit

         21. Undergone major surgery requiring general anaesthesia or a respiratory assistance
             device within 4 weeks prior to the baseline visit (within 2 weeks for video-assisted
             thoracoscopic surgery [VATS] or open-and-closed [ONC] surgery)

         22. Treated with other investigational drugs within 4 weeks prior to the baseline visit
             for this study

         23. Pregnant* or lactating females, and females/males of childbearing potential who do not
             agree to a reliable and adequate method of contraception

         24. A known history of severe drug hypersensitivity or hypersensitivity to a therapy
             similar to the study drugs

         25. Unable to participate in the trial according to the investigator's decision

         26. Previous therapy with vascular endothelial growth factor (VEGF)-targeted agents
             including (but not limited to) bevacizumab

         27. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
             CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or
             higher irAE

         28. Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form
             of systemic treatment and is allowed

         29. Known human immunodeficiency virus (HIV) infection. No HIV testing is required unless
             mandated by local health authority

         30. Known active hepatitis B or hepatitis C infection. No testing for hepatitis B and
             hepatitis C is required unless mandated by local health authority

         31. Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines
             that do not contain live virus are permitted

         32. Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior
             to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

